CoChat

The role of IFN in the development of NAFLD and NASH

Møhlenberg, Michelle, Terczynska-Dyla, Ewa, Thomsen, Karen Louise, George, Jacob, Eslam, Mohammed, Grønbæk, Henning, Hartmann, Rune · 2019 · Cytokine
Cited by 50

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Non-alcoholic fatty liver disease (NAFLD) and its progressive inflammatory form non-alcoholic steatohepatitis (NASH) are major health challenges due to a significant increase in their incidence and prevalence. While NAFLD is largely benign, the chronic liver inflammation in NASH patients may cause progression to liver cirrhosis and hepatocellular carcinoma. There is an urgent need for a better understanding of the factors, which drive the progression from NAFLD to NASH and how to use this information both to improve diagnostic and to develop new treatment strategies. Increasing evidence points to interferons (IFNs) as key players in NAFLD and particular in the progression to NASH. IFNs crucial role in disease development is supported by both genetic evidence and animal studies. In this review, we describe the involvement of both type I and type III IFNs in the development and progression of NAFLD and NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cyto.2018.08.013

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 79

  1. Adams, 2007, Nonalcoholic fatty liver disease, Ann. Epidemiol., 17, 863, 10.1016/j.annepidem.2007.05.013 · DOI · Paper page
  2. Wong, 2015, Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States, Gastroenterology, 148, 547, 10.1053/j.gastro.2014.11.039 · DOI · Paper page
  3. McCullough, 2004, The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease, Clin. Liver Dis., 8, 521, 10.1016/j.cld.2004.04.004 · DOI · Paper page
  4. Starley, 2010, Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection, Hepatology, 51, 1820, 10.1002/hep.23594 · DOI · Paper page
  5. Day, 1998, Steatohepatitis: a tale of two “hits”?, Gastroenterology, 114, 842, 10.1016/S0016-5085(98)70599-2 · DOI · Paper page
  6. Silverman, 1990, Liver pathology in morbidly obese patients with and without diabetes, Am. J. Gastroenterol., 85, 1349
  7. Andersen, 1984, The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study, Int. J. Obes., 8, 107
  8. Poonawala, 2000, Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study, Hepatology, 32, 689, 10.1053/jhep.2000.17894 · DOI · Paper page
  9. Clark, 2002, Hepatic steatosis and type 2 diabetes mellitus, Curr. Diab. Rep., 2, 210, 10.1007/s11892-002-0085-3 · DOI
  10. Gupte, 2004, Non-alcoholic steatohepatitis in type 2 diabetes mellitus, J. Gastroenterol. Hepatol., 19, 854, 10.1111/j.1440-1746.2004.03312.x · DOI · Paper page
  11. Assy, 2000, Fatty infiltration of liver in hyperlipidemic patients, Dig. Dis. Sci., 45, 1929, 10.1023/A:1005661516165 · DOI · Paper page
  12. Berkowitz, 1964, Metabolic changes associated with obesity before and after weight reduction, JAMA, 187, 399, 10.1001/jama.1964.03060190015003 · DOI
  13. Donati, 2004, Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance, Gut, 53, 1020, 10.1136/gut.2003.027086 · DOI · Paper page
  14. Lau, 2015, Gut microbiota: association with NAFLD and metabolic disturbances, Biomed. Res. Int., 2015, 10.1155/2015/979515 · DOI · Paper page
  15. Valenti, 2010, Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease, Hepatology, 51, 1209, 10.1002/hep.23622 · DOI · Paper page
  16. Eslam, 2016, Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes, Hepatology, 64, 34, 10.1002/hep.28475 · DOI · Paper page
  17. Mancina, 2016, The MBOAT7-TMC4 Variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent, Gastroenterology, 150, 1219, 10.1053/j.gastro.2016.01.032 · DOI · Paper page
  18. Thabet, 2016, MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C, Nat. Commun., 7, 12757, 10.1038/ncomms12757 · DOI · Paper page
  19. Thabet, 2017, The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B, Hepatology, 65, 1840, 10.1002/hep.29064 · DOI · Paper page
  20. Petta, 2012, IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease, J. Hepatol., 56, 1356, 10.1016/j.jhep.2012.01.007 · DOI
  21. Petta, 2017, Interferon lambda 4 rs368234815 TT>deltaG variant is associated with liver damage in patients with nonalcoholic fatty liver disease, Hepatology, 66, 1885, 10.1002/hep.29395 · DOI · Paper page
  22. Eslam, 2015, Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease, Nat. Commun., 6, 6422, 10.1038/ncomms7422 · DOI · Paper page
  23. Schreiber, 2017, The molecular basis for differential type I interferon signaling, J. Biol. Chem., 292, 7285, 10.1074/jbc.R116.774562 · DOI · Paper page
  24. Wack, 2015, Guarding the frontiers: the biology of type III interferons, Nat. Immunol., 16, 802, 10.1038/ni.3212 · DOI · Paper page
  25. Dickensheets, 2013, Interferon-lambda (IFN-lambda) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes, J. Leukoc. Biol., 93, 377, 10.1189/jlb.0812395 · DOI
  26. Lauber, 2015, Transcriptome analysis reveals a classical interferon signature induced by IFN lambda 4 in human primary cells, Genes Immun., 16, 414, 10.1038/gene.2015.23 · DOI
  27. Muir, 2014, A randomized Phase 2b Study of peginterferon lambda-1a for the treatment of chronic HCV infection, J. Hepatol., 10.1016/j.jhep.2014.07.022 · DOI
  28. Hermant, 2014, Interferon-lambda in the context of viral infections: production, response and therapeutic implications, J. Innate Immun., 6, 563, 10.1159/000360084 · DOI
  29. Durbin, 2013, Interferon induction and function at the mucosal surface, Immunol. Rev., 255, 25, 10.1111/imr.12101 · DOI · Paper page
  30. Chen, 2016, Evolution of IFN-lambda in tetrapod vertebrates and its functional characterization in green anole lizard (Anolis carolinensis), Dev. Comp. Immunol., 61, 208, 10.1016/j.dci.2016.04.004 · DOI
  31. Key, 2014, Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4), PLoS Genet., 10, 10.1371/journal.pgen.1004681 · DOI
  32. Prokunina-Olsson, 2013, A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus, Nat. Genet., 45, 164, 10.1038/ng.2521 · DOI · Paper page
  33. McFarland, 2014, The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs, Nat. Immunol., 15, 72, 10.1038/ni.2758 · DOI
  34. Tanaka, 2009, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C, Nat. Genet., 41, 1105, 10.1038/ng.449 · DOI · Paper page
  35. Suppiah, 2009, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy, Nat. Genet., 41, 10.1038/ng.447 · DOI · Paper page
  36. Smith, 2011, Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort, Genome Med., 3, 57, 10.1186/gm273 · DOI
  37. Terczynska-Dyla, 2014, Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes, Nat. Commun., 5, 5699, 10.1038/ncomms6699 · DOI
  38. Bochud, 2012, IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes, Hepatology, 55, 384, 10.1002/hep.24678 · DOI
  39. Eslam, 2017, IFN-lambda 3, not IFN-lambda 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis, Nat. Genet., 49, 795, 10.1038/ng.3836 · DOI
  40. Eslam, 2017, IFN-lambda3, not IFN-lambda4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis, Nat. Genet., 49, 795, 10.1038/ng.3836 · DOI
  41. Heim, 2014, Innate and adaptive immune responses in HCV infections, J. Hepatol., 61, S14, 10.1016/j.jhep.2014.06.035 · DOI · Paper page
  42. Shrivastava, 2016, Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis, Hepatol. Int., 10, 937, 10.1007/s12072-016-9733-6 · doi:10.1007/s12072-016-9733-6
  43. Hannibal, 2017, Deficiency in plasmacytoid dendritic cells and type I interferon signalling prevents diet-induced obesity and insulin resistance in mice, Diabetologia, 60, 2033, 10.1007/s00125-017-4341-0 · DOI · Paper page
  44. Roh, 2014, Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis, Hepatology, 60, 237, 10.1002/hep.26981 · DOI · Paper page
  45. Mitsumoto, 2017, Time-course microarrays reveal early activation of the immune transcriptome in a choline-deficient mouse model of liver injury, Life Sci., 184, 103, 10.1016/j.lfs.2017.07.009 · DOI
  46. Wieser, 2016, Adipose type I interferon signalling protects against metabolic dysfunction, Gut
  47. Kumari, 2016, IRF3 promotes adipose inflammation and insulin resistance and represses browning, J. Clin. Invest., 126, 2839, 10.1172/JCI86080 · DOI · Paper page
  48. Wang, 2013, Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance, Am. J. Physiol. Endocrinol. Metab., 305, 10.1152/ajpendo.00505.2012 · DOI · Paper page
  49. Alzaid, 2016, IRF5 governs liver macrophage activation that promotes hepatic fibrosis in mice and humans, JciInsight, 1
  50. Qiao, 2017, Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease, Metabolism
  51. Wang, 2014, Interferon regulatory factor 3 constrains IKKbeta/NF-kappaB signaling to alleviate hepatic steatosis and insulin resistance, Hepatology, 59, 870, 10.1002/hep.26751 · DOI · Paper page
  52. Eguchi, 2013, Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization, Diabetes, 62, 3394, 10.2337/db12-1327 · DOI · Paper page
  53. Wang, 2013, Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice, Hepatology, 58, 603, 10.1002/hep.26368 · DOI · Paper page
  54. Csak, 2011, Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice, Hepatology, 53, 1917, 10.1002/hep.24301 · DOI
  55. Ilan, 2012, Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis, World J. Gastroenterol., 18, 2609, 10.3748/wjg.v18.i21.2609 · DOI · Paper page
  56. Enomoto, 2001, Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin, Alcohol Clin. Exp. Res., 25
  57. Miura, 2013, Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice, Hepatology, 57, 577, 10.1002/hep.26081 · DOI · Paper page
  58. Kawai, 2007, TLR signaling, Semin. Immunol., 19, 24, 10.1016/j.smim.2006.12.004 · DOI · Paper page
  59. Jialal, 2014, Toll-like receptor status in obesity and metabolic syndrome: a translational perspective, J. Clin. Endocrinol. Metab., 99, 39, 10.1210/jc.2013-3092 · DOI · Paper page
  60. O'Neill, 2008, When signaling pathways collide: positive and negative regulation of Toll-like receptor signal transduction, Immunity, 29, 12, 10.1016/j.immuni.2008.06.004 · DOI · Paper page
  61. Fujihara, 2003, Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex, Pharmacol. Ther., 100, 171, 10.1016/j.pharmthera.2003.08.003 · DOI · Paper page
  62. Spruss, 2009, Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice, Hepatology, 50, 1094, 10.1002/hep.23122 · DOI · Paper page
  63. Csak, 2011, Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice, Am. J. Physiol. Gastrointest. Liver Physiol., 300, 10.1152/ajpgi.00163.2009 · DOI · Paper page
  64. Poggi, 2007, C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet, Diabetologia, 50, 1267, 10.1007/s00125-007-0654-8 · DOI · Paper page
  65. Szabo, 2005, Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4, Alcohol Clin. Exp. Res., 29
  66. Rivera, 2010, Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis, BMC Gastroenterol., 10, 52, 10.1186/1471-230X-10-52 · DOI · Paper page
  67. Ehses, 2010, Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet, Diabetologia, 53, 1795, 10.1007/s00125-010-1747-3 · DOI · Paper page
  68. Himes, 2010, Tlr2 is critical for diet-induced metabolic syndrome in a murine model, Faseb J., 24, 731, 10.1096/fj.09-141929 · DOI · Paper page
  69. Vijay-Kumar, 2007, Deletion of TLR5 results in spontaneous colitis in mice, J. Clin. Invest., 117, 3909
  70. Letran, 2011, TLR5-deficient mice lack basal inflammatory and metabolic defects but exhibit impaired CD4 T cell responses to a flagellated pathogen, J. Immunol. (Baltimore, Md. : 1950), 186, 5406, 10.4049/jimmunol.1003576 · DOI · Paper page
  71. Guo, 2015, Inflammasomes: mechanism of action, role in disease, and therapeutics, Nat. Med., 21, 677, 10.1038/nm.3893 · DOI · Paper page
  72. Szabo, 2015, Inflammasome activation in the liver: focus on alcoholic and non-alcoholic steatohepatitis, Clin. Res. Hepatol. Gastroenterol., 39, S18, 10.1016/j.clinre.2015.06.012 · DOI
  73. Wen, 2011, Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling, Nat. Immunol., 12, 408, 10.1038/ni.2022 · DOI · Paper page
  74. Eslam, 2016, Targeting IFN-: therapeutic implications, Expert Opin. Ther. Targets, 20, 1425, 10.1080/14728222.2016.1241242 · DOI
  75. Read, 2017, Zinc is a potent and specific inhibitor of IFN-lambda 3 signalling, Nat. Commun., 8
  76. Eslam, 2016, FibroGENE: a gene-based model for staging liver fibrosis, J. Hepatol., 64, 390, 10.1016/j.jhep.2015.11.008 · DOI · Paper page
  77. Li, 2017, Comprehensive variation discovery and recovery of missing sequence in the pig genome using multiple de novo assemblies, Genome Res., 27, 865, 10.1101/gr.207456.116 · DOI · Paper page
  78. Zhang, 2017, Transcriptome analyses reveal genes and pathways associated with fatty acid composition traits in pigs, Anim. Genet., 48, 645, 10.1111/age.12597 · DOI
  79. Liang, 2015, Liver injury and fibrosis induced by dietary challenge in the Ossabaw miniature Swine, PLoS One, 10, 10.1371/journal.pone.0124173 · DOI

Cited by

See all 50

Metadata

Authors
Møhlenberg, M., Terczynska-Dyla, E., Thomsen, K. L., George, J., Eslam, M., Grønbæk, H., & Hartmann, R.
Venue
Cytokine
Publisher
Elsevier BV
Published
2019-12
Volume
124
Pages
154519
ISSN
1043-4666 (ISSN-L)
OpenAlex
W2888229165
Cited by
50
References
16
FWCI
3.07
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of IFN in the development of NAFLD and NASH. https://app.cochat.ai/papers/10.1016/j.cyto.2018.08.013
The paper
Møhlenberg, M., Terczynska-Dyla, E., Thomsen, K. L., George, J., Eslam, M., Grønbæk, H., & Hartmann, R. (2019). The role of IFN in the development of NAFLD and NASH. Cytokine. https://doi.org/10.1016/j.cyto.2018.08.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.